134 related articles for article (PubMed ID: 12168822)
1. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503.
Hill SA; Toze GM; Pettit GR; Chaplin DJ
Anticancer Res; 2002; 22(3):1453-8. PubMed ID: 12168822
[TBL] [Abstract][Full Text] [Related]
2. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.
Hua J; Sheng Y; Pinney KG; Garner CM; Kane RR; Prezioso JA; Pettit GR; Chaplin DJ; Edvardsen K
Anticancer Res; 2003; 23(2B):1433-40. PubMed ID: 12820406
[TBL] [Abstract][Full Text] [Related]
3. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
Davis PD; Dougherty GJ; Blakey DC; Galbraith SM; Tozer GM; Holder AL; Naylor MA; Nolan J; Stratford MR; Chaplin DJ; Hill SA
Cancer Res; 2002 Dec; 62(24):7247-53. PubMed ID: 12499266
[TBL] [Abstract][Full Text] [Related]
4. Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model.
Shnyder SD; Cooper PA; Pettit GR; Lippert JW; Bibby MC
Anticancer Res; 2003; 23(2B):1619-23. PubMed ID: 12820431
[TBL] [Abstract][Full Text] [Related]
5. Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models.
Hill SA; Chaplin DJ; Lewis G; Tozer GM
Int J Cancer; 2002 Nov; 102(1):70-4. PubMed ID: 12353236
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate.
Holwell SE; Cooper PA; Thompson MJ; Pettit GR; Lippert LW; Martin SW; Bibby MC
Anticancer Res; 2002; 22(6C):3933-40. PubMed ID: 12553015
[TBL] [Abstract][Full Text] [Related]
7. Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours.
Holwell SE; Cooper PA; Grosios K; Lippert JW; Pettit GR; Shnyder SD; Bibby MC
Anticancer Res; 2002; 22(2A):707-11. PubMed ID: 12017147
[TBL] [Abstract][Full Text] [Related]
8. Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide.
Parkins CS; Holder AL; Hill SA; Chaplin DJ; Tozer GM
Br J Cancer; 2000 Sep; 83(6):811-6. PubMed ID: 10952787
[TBL] [Abstract][Full Text] [Related]
9. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.
Galbraith SM; Chaplin DJ; Lee F; Stratford MR; Locke RJ; Vojnovic B; Tozer GM
Anticancer Res; 2001; 21(1A):93-102. PubMed ID: 11299795
[TBL] [Abstract][Full Text] [Related]
10. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
11. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
Dark GG; Hill SA; Prise VE; Tozer GM; Pettit GR; Chaplin DJ
Cancer Res; 1997 May; 57(10):1829-34. PubMed ID: 9157969
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma.
Grosios K; Loadman PM; Swaine DJ; Pettit GR; Bibby MC
Anticancer Res; 2000; 20(1A):229-33. PubMed ID: 10769660
[TBL] [Abstract][Full Text] [Related]
13. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate.
Chaplin DJ; Pettit GR; Hill SA
Anticancer Res; 1999; 19(1A):189-95. PubMed ID: 10226542
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
[TBL] [Abstract][Full Text] [Related]
15. Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model.
Malcontenti-Wilson C; Muralidharan V; Skinner S; Christophi C; Sherris D; O'Brien PE
Clin Cancer Res; 2001 Apr; 7(4):1052-60. PubMed ID: 11309357
[TBL] [Abstract][Full Text] [Related]
16. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
17. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug.
Grosios K; Holwell SE; McGown AT; Pettit GR; Bibby MC
Br J Cancer; 1999 Dec; 81(8):1318-27. PubMed ID: 10604728
[TBL] [Abstract][Full Text] [Related]
18. Vascular targeting agent Oxi4503 inhibits tumor growth in a colorectal liver metastases model.
Malcontenti-Wilson C; Chan L; Nikfarjam M; Muralidharan V; Christophi C
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e96-e104. PubMed ID: 17559382
[TBL] [Abstract][Full Text] [Related]
19. Low-dose combretastatin A4 phosphate enhances the immune response of tumor hosts to experimental colon carcinoma.
Badn W; Kalliomäki S; Widegren B; Sjögren HO
Clin Cancer Res; 2006 Aug; 12(15):4714-9. PubMed ID: 16899622
[TBL] [Abstract][Full Text] [Related]
20. The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization.
Hokland SL; Horsman MR
Int J Hyperthermia; 2007 Nov; 23(7):599-606. PubMed ID: 18038290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]